Cardiotoxicity From Human Epidermal Growth Factor Receptor-2 (HER2) Targeted Therapies

J Am Heart Assoc. 2017 Sep 22;6(9):e006915. doi: 10.1161/JAHA.117.006915.

Authors

Roberta Florido¹, Karen L Smith², Kimberly K Cuomo³, Stuart D Russell³

Affiliations

¹ Division of Cardiology, Johns Hopkins University, Baltimore, MD rflorid1@jhmi.edu.
² Breast and Ovarian Cancer Program, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.
³ Division of Cardiology, Johns Hopkins University, Baltimore, MD.

No abstract available

Keywords: breast cancer; cardiotoxicity; heart failure; human epidermal growth factor‐2; trastuzumab.

Publication types

Review

MeSH terms

Animals
Antineoplastic Agents / adverse effects*
Breast Neoplasms / drug therapy*
Breast Neoplasms / enzymology
Breast Neoplasms / genetics
Breast Neoplasms / pathology
Cardiotoxicity
Female
Heart / drug effects*
Heart / physiopathology
Heart Diseases / chemically induced*
Heart Diseases / pathology
Heart Diseases / physiopathology
Heart Diseases / prevention & control
Humans
Molecular Targeted Therapy / adverse effects*
Myocardium / pathology
Protein Kinase Inhibitors / adverse effects*
Receptor, ErbB-2 / antagonists & inhibitors*
Receptor, ErbB-2 / genetics
Receptor, ErbB-2 / metabolism
Risk Assessment
Risk Factors
Signal Transduction / drug effects

Substances

Antineoplastic Agents
Protein Kinase Inhibitors
ERBB2 protein, human
Receptor, ErbB-2